Only the symptoms of ataxia, such as weakness and mobility issues, may be treated as the disease has no known treatment. Spinocerebellar ataxia, Friedreich's ataxia, ataxia-telangiectasia, multiple system atrophy (MSA), episodic ataxia, and other kinds of ataxia exist. Ataxia is becoming more common. In the pharmaceutical sector, key companies are focused on filing applications for approval of medicines therapy for the treatment of ataxia, which is likely to fuel growth in the global ataxia market throughout the forecast period. The rarity of ataxia illness is a key impediment to performing clinical studies for its treatment, which is projected to stymie growth in the worldwide ataxia market throughout the forecast period. Because of the link of ataxia with COVID-19, the COVID-19 pandemic is projected to have a favourable influence on the worldwide ataxia market. According to a March 2021 article published in the journal Movement Disorders Clinical Practice, several neurological manifestations of COVID-19 have been reported globally, ranging from mild conditions such as headache, confusion, focal seizures, ataxia to severe life-threatening conditions such as Guillain Barre Syndrome, acute haemorrhagic necrotizing encephalopathy, and others.
According to Coherent Market Insights, the global Ataxia Market is estimated to be valued at US$ 30,880.5 million in 2021 and is expected to exhibit a CAGR of 9.4% over the forecast period (2021-2028).
Key Competitors in the Ataxia Industry:
1. Pfizer, Inc.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sell biopharmaceutical products worldwide
2. CRISPR Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
3. Acorda Therapeutics
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
4. Capsida Biotherapeutics Inc.
Capsida is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders. It features a proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the diseased organ. The company is headquartered in U.S., founded in 2019.
